



1Fw

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on MARCH 28, 2007

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT

Patent Application  
Docket No. ARS-131  
Serial No. 10/593,432

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kinsey Maundrell  
Serial No. : 10/593,432  
Filed : September 18, 2006  
Conf. No. : 9885  
For : Anti-Lipid Rafts Antibodies

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicant has not submitted copies of the U.S. patents or published U.S. Patent Application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

A handwritten signature in black ink, reading "Frank C. Eisenschenk". The signature is written in a cursive style with a large, stylized "F" and "E".

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/bra

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/593,432	
			Filing Date	September 18, 2006	
			First Named Inventor	Kinsey Maundrell	
			Art Unit		
			Examiner Name		
Sheet	1	of	5	Attorney Docket Number	ARS-131

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2002/0128175 A1	09-12-2002	Anantharamaiah	All
	U2	US-5,134,121	07-28-1992	Mobley <i>et al.</i>	All
	U3	US-5,276,059	01-04-1994	Caughey <i>et al.</i>	All
	U4	US-5,948,763	09-07-1999	Soto-Jara <i>et al.</i>	All
	U5	US-6,197,972 B1	03-06-2001	Heeres <i>et al.</i>	All
	U6	US-6,355,610 B2	03-12-2002	Chesebro <i>et al.</i>	All
	U7	US-6,552,922 B2	04-22-2003	Ogiwara <i>et al.</i>	All
	U8	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1	WO 01/68710	A1	09-20-2001	Applied Research Systems ARS Holding N.V.	All
	F2	WO 02/04954	A2	01-17-2002	Applied Research Systems ARS Holding N.V.	All
	F3	WO 03/002533	A1	01-09-2003	Pfizer Products Inc.	All
	F4	WO 03/045921	A1	06-05-2003	Fujisawa Pharmaceutical Co., Ltd.; Daiso Co., Ltd.	All
	F5					
	F6					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

5

Application Number

10/593,432

Filing Date

September 18, 2006

First Named Inventor

Kinsey Maundrell

Group Art Unit

Examiner Name

Attorney Docket Number

ARS-131

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	AIZAWA, Y. <i>et al.</i> "Amino-Terminus Truncated Apolipoprotein E is the Major Species in Amyloid Deposits in Alzheimer's Disease-Affected Brains: A Possible Role for Apolipoprotein E in Alzheimer's Disease" <i>Brain Research</i> , 1997, pp. 208-214, Vol. 768.	
	R2	BARON, G. S. <i>et al.</i> "Conversion of Raft Associated Prion Protein to the Protease-Resistant State Requires Insertion of PrP-res (PrP <sup>Sc</sup> ) into Contiguous Membranes" <i>The EMBO Journal</i> , 2002, pp. 1031-1040, Vol. 21, No. 5.	
	R3	BOSQUE, P. J. <i>et al.</i> "Cultured Cell Sublines Highly Susceptible to Prion Infection" <i>Journal of Virology</i> , May 2000, pp. 4377-4386, Vol. 74, No. 9.	
	R4	BRIMACOMBE, D. B. <i>et al.</i> "Characterization and Polyanion-Binding Properties of Purified Recombinant Prion Protein" <i>Biochem. J.</i> , 1999, pp. 605-613, Vol. 342.	
	R5	BRUCE, M. E. "Transmissions to Mice Indicate that 'New Variant' CJD is Caused by the BSE Agent" <i>Nature</i> , October 2, 1997, pp. 498-501, Vol. 389.	
	R6	BÜELER, H. <i>et al.</i> "Mice Devoid of PrP are Resistant to Scrapie" <i>Cell.</i> , July 2, 1993, pp. 1339-1347, Vol. 73.	
	R7	CHABRY, J. <i>et al.</i> "Specific Inhibition of <i>in Vitro</i> Formation of Protease-Resistant Prion Protein by Synthetic Peptides" <i>The Journal of Biological Chemistry</i> , May 22, 1998, pp. 13203-13207, Vol. 273, No. 21.	
	R8	CHOI, S. Y. <i>et al.</i> "Dissociation of LPL and LDL: Effects of Lipoproteins and Anti-apoB Antibodies" <i>Journal of Lipid Research</i> , 1997, pp. 77-85, Vol. 38.	
	R9	COHEN, F. E. <i>et al.</i> "Pathologic Conformations of Prion Proteins" <i>Annu. Rev. Biochem.</i> , 1998, pp. 793-819, Vol. 67.	
	R10	CORDEIRO, Y. <i>et al.</i> "DNA Converts Cellular Prion Protein into the $\beta$ -Sheet Conformation and Inhibits Prion Peptide Aggregation" <i>The Journal of Biological Chemistry</i> , December 28, 2001, pp. 49400-49409, Vol. 276, No. 52.	
	R11	DEBBURMAN, S. K. <i>et al.</i> "Chaperone-Supervised Conversion of Prion Protein to its Protease-Resistant Form" <i>Proc. Natl. Acad. Sci. USA</i> , December 1997, pp. 13938-13943, Vol. 94.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

5

Application Number

10/593,432

Filing Date

September 18, 2006

First Named Inventor

Kinsey Maundrell

Group Art Unit

Examiner Name

Attorney Docket Number

ARS-131

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R12	EDENHOFER, F. <i>et al.</i> "Prion Protein PrP <sup>c</sup> Interacts with Molecular Chaperones of the Hsp60 Family" <i>Journal of Virology</i> , July 1996, pp. 4724-4728, Vol. 70, No. 7.	
	R13	ENARI, M. <i>et al.</i> "Scrapie Prion Protein Accumulation by Scrapie-Infected Neuroblastoma Cells Abrogated by Exposure to a Prion Protein Antibody" <i>PNAS</i> , July 31, 2001, pp. 9295-9299, Vol. 98, No. 16.	
	R14	FIVAZ, M. <i>et al.</i> "Analysis of Glycosyl Phosphatidylinositol-Anchored Proteins by Two-Dimensional Gel Electrophoresis" <i>Electrophoresis</i> , 2000, pp. 3351-3356, Vol. 21.	
	R15	HOOPER, N. M. "Detergent-Insoluble Glycosphingolipid/Cholesterol-Rich Membrane Domains, Lipid Rafts and Caveolae (Review)" <i>Molecular Membrane Biology</i> , 1999, pp. 145-156, Vol. 16.	
	R16	JIN, T. <i>et al.</i> "The Chaperone Protein BiP Binds to a Mutant Prion Protein and Mediates Its Degradation by the Proteasome" <i>The Journal of Biological Chemistry</i> , December 8, 2000, pp. 38699-38704, Vol. 275, No. 49.	
	R17	KANEKO, K. <i>et al.</i> "Evidence for Protein X Binding to a Discontinuous Epitope on the Cellular Prion Protein During Scrapie Prion Propagation" <i>Proc. Natl. Acad. Sci. USA</i> , September 1997, pp. 10069-10074, Vol. 94.	
	R18	MARTINS, V. R. <i>et al.</i> "Cellular Prion Protein: On the Road for Functions" <i>FEBS Letters</i> , 2002, pp. 25-28, Vol. 512.	
	R19	NANDI, P. K. <i>et al.</i> "DNA-Induced Partial Unfolding of Prion Protein Leads to its Polymerisation to Amyloid" <i>J. Mol. Biol.</i> , 2002, pp. 153-161, Vol. 322.	
	R20	PAN, K.-M. <i>et al.</i> "Conversion of $\alpha$ -helices into $\beta$ -Sheets Features in the Formation of the Scrapie Prion Proteins" <i>Proc. Natl. Acad. Sci. USA</i> , December 1993, pp. 10962-10966, Vol. 90.	
	R21	PERETZ, D. <i>et al.</i> "Antibodies Inhibit Prion Propagation and Clear Cell Cultures of Prion Infectivity" <i>Nature</i> , August 16, 2001, pp. 739-743, Vol. 412.	
	R22	PRUSINER, S. B. "Molecular Biology of Prion Diseases" <i>Science</i> , June 14, 1991, pp. 1515-1522, Vol. 252.	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

5

Application Number

10/593,432

Filing Date

September 18, 2006

First Named Inventor

Kinsey Maundrell

Group Art Unit

Examiner Name

Attorney Docket Number

ARS-131

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R23	PRUSINER, S. B. "Prions" <i>Proc. Natl. Acad. Sci. USA</i> November 1998, pp. 13363-13383, Vol. 95.	
	R24	ROOS, R. <i>et al.</i> "The Clinical Characteristics of Transmissible Creutzfeldt-Jakob Disease" <i>Brain</i> , 1973, pp. 1-20, Vol. 96.	
	R25	SABORIO, G. P. <i>et al.</i> "Cell-Lysate Conversion of Prion Protein into its Protease-Resistant Isoform Suggests the Participation of a Cellular Chaperone" <i>Biochemical and Biophysical Research Communications</i> , 1999, pp. 470-475, Vol. 258.	
	R26	SCHMITT-ULMS, G. <i>et al.</i> "Binding of Neural Cell Adhesion Molecules (N-CAMs) to the Cellular Prion Protein" <i>J. Mol. Biol.</i> , 2001, pp. 1209-1225, Vol. 314.	
	R27	SCOTT, M. R. <i>et al.</i> "Compelling Transgenic Evidence for Transmission of Bovine Spongiform Encephalopathy Prions to Humans" <i>PNAS</i> , December 21, 1999, pp. 15137-15142, Vol. 96, No. 26.	
	R28	SEGREST, J. P. <i>et al.</i> "Structure of Apolipoprotein B-100 in Low Density Lipoproteins" <i>Journal of Lipid Research</i> , 2001, pp. 1346-1367, Vol. 42.	
	R29	SIMONS, K. <i>et al.</i> "Lipid Rafts and Signal Transduction" <i>Nature Reviews: Molecular Cell Biology</i> , October 2000, pp. 31-41, Vol. 1.	
	R30	SOTO, C. <i>et al.</i> "Prions: Disease Propagation and Disease Therapy by Conformational Transmission" <i>TRENDS in Molecular Medicine</i> , March 2001, pp. 109-114, Vol. 7, No. 3.	
	R31	TARABOULOS, A. <i>et al.</i> "Cholesterol Depletion and Modification of COOH-Terminal Targeting Sequence of the Prion Protein Inhibit Formation of the Scrapie Isoform" <i>The Journal of Cell Biology</i> , April 1995, pp. 121-132, Vol. 129, No. 1.	
	R32	TELLING, G. C. <i>et al.</i> "Transmission of Creutzfeldt-Jakob Disease from Humans to Transgenic Mice Expressing Chimeric Human-Mouse Prion Protein" <i>Proc. Natl. Acad. Sci. USA</i> , October 1994, pp. 9936-9940, Vol. 91.	
	R33	TSUI-PIERCHALA, B. A. <i>et al.</i> "Lipid Rafts in Neuronal Signaling and Function" <i>TRENDS in Neurosciences</i> , August 2002, pp. 412-417, Vol. 25, No. 8.	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/593,432
Filing Date	September 18, 2006
First Named Inventor	Kinsey Maundrell
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARS-131

Sheet	5	of	5
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R34	WANG, X. <i>et al.</i> "Well-Defined Regions of Apolipoprotein B-100 Undergo Conformational Change During its Intravascular Metabolism" <i>Arterioscler Thromb Vasc Biol.</i> , May 2000, pp. 1301-1308, Vol. 20.	
	R35	WILL, R. G. <i>et al.</i> "A New Variant of Creutzfeldt-Jakob Disease in the UK" <i>The Lancet</i> , April 6, 1996, pp. 921-925, Vol. 347.	
	R36	YAMADA, T. <i>et al.</i> "Further Characterization of a Monoclonal Antibody Recognizing Apolipoprotein E Peptides in Amyloid Deposits" <i>Annals of Clinical and Laboratory Science</i> , pp. 276-281, Vol. 27, No. 4.	
	R37		
	R38		
	R39		
	R40		
	R41		
	R42		
	R43		
	R44		
	R45		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.